Agios Pharmaceuticals AGIO Weighted Average Exercise Price of Vested and Expected to Vest Options
Weighted Average Exercise Price of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's weighted average exercise price of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Agios Pharmaceuticals's weighted average exercise price of vested and expected to vest options?
- Agios Pharmaceuticals (AGIO) reported weighted average exercise price of vested and expected to vest options of $38.45 in Q1 2026.
- How has Agios Pharmaceuticals's weighted average exercise price of vested and expected to vest options changed year-over-year?
- Agios Pharmaceuticals's weighted average exercise price of vested and expected to vest options decreased by 5.6% year-over-year, from $40.73 to $38.45.